Introduction {#s1}
============

*Aspergillus* species are common environmental fungi found in soil and decaying vegetative materials. They can infect immunocompetent (Chaturvedi et al., [@B18]; Emiralioglu et al., [@B29]; Kumar et al., [@B55]; Saedi et al., [@B83]) and immunocompromised (Taccone et al., [@B91]) patients. Individuals with underlying diseases or immune deficiencies can develop a variety of symptoms ranging from allergies, bronchopulmonary infections, and bronchitis, to invasive aspergillosis (IA) (Ruping et al., [@B82]; Guinea et al., [@B37]; Sugui et al., [@B87]). IA is associated mainly with neutropenic patients suffering from hematological malignancies (Gerson et al., [@B33]; Abers et al., [@B2]). Other risk factors include hematopoietic stem cell transplant (HSCT) (Marr et al., [@B61]), solid organ transplant (SOT) (Patterson et al., [@B75]), patients receiving prolonged high doses of corticosteroids (Palmer et al., [@B73]; Lewis and Kontoyiannis, [@B58]), human immunodeficiency virus (HIV) infection with advanced acquired immune-deficiency syndrome (AIDS) (Libanore et al., [@B59]) and chronic granulomatous disease (CGD) (Beaute et al., [@B10]). IA is associated with a high mortality rate among immunocompromised patients (Baddley et al., [@B7]; Kontoyiannis et al., [@B50]; Neofytos et al., [@B70]; Garcia-Vidal et al., [@B31]). During the last two decades, species other than *A. fumigatus*, namely, *Aspergillus flavus, Aspergillus terreus, Aspergillus niger*, and other cryptic and rare species have increasingly been isolated from clinical specimens (Lass-Florl et al., [@B57]; Krishnan et al., [@B53]; Alastruey-Izquierdo et al., [@B5]). This epidemiological shift is attributed to the increasing number of immunocompromised patients, advances in the detection and identification of pathogenic fungi, and the selective pressure caused by extensive use of broad-spectrum antifungal drugs (Krishnan et al., [@B53]; Alastruey-Izquierdo et al., [@B5]). Voriconazole is the first line therapy recommended for the management of IA (Patterson et al., [@B76]; Ullmann et al., [@B96]). Other alternatives are liposomal amphotericin B and isavuconazole. In patients who exhibit refractory or progressive IA after the initiation of primary therapy, an additional antifungal agent may be added or a combination of antifungal agents from different classes (e.g., a triazole and an echinocandin) may be considered (Patterson et al., [@B76]; Ullmann et al., [@B96]). Posaconazole can be used as prophylaxis for patients at high risk for IA (Patterson et al., [@B76]; Ullmann et al., [@B96]). Triazole-resistant *Aspergillus*, particularly *A. fumigatus*, became a worldwide problem, with high prevalence in Europe (Alastruey-Izquierdo et al., [@B6]; Abdolrasouli et al., [@B1]; Buil et al., [@B14]) and recently in the United States (Berkow et al., [@B11]). This poses a great challenge for clinicians in patient management. Triazole resistance in *Aspergillus* has also been reported from other parts of the world, such as India (Chowdhary et al., [@B20]), Iran (Seyedmousavi et al., [@B84]; Mohammadi et al., [@B64]; Nabili et al., [@B66]), and Tanzania (Chowdhary et al., [@B21]). In the Middle East, apart from Iran, triazole resistance for *A. fumigatus* has also been documented in Kuwait, a neighboring Arabian gulf country, in outdoor and hospital environments (Ahmad et al., [@B4]) as well as from clinical samples (Ahmad et al., [@B3]).

The aim of the current study was to characterize 70 *Aspergillus* species isolated from a variety of clinical specimens received at the microbiology laboratory of Hamad general hospital in Doha, Qatar, with emphasis on emerging rare species identified as human pathogens, and to determine their antifungal susceptibility patterns using the Clinical and Laboratory Standards Institute (CLSI) M38-A2 reference method.

Materials and Methods {#s2}
=====================

Patients and Specimens
----------------------

Seventy *Aspergillus species* were recovered from clinical specimens of 67 patients, including immunocompromised patients (*n* = 17, 25.4%) and immunocompetent ones with other underlying diseases (*n* = 50, 74.6%) ([Table 1](#T1){ref-type="table"}), presented at Hamad general hospital in Doha, Qatar, between August 2003 and November 2014 with proven or probable infection or colonization by *Aspergillus* species. The patients represented 15 nationalities, including countries from Southeast Asia (*n* = 23, 23.3%) and the Middle East (*n* = 42, 62.7%), South Africa (*n* = 1, 1.5%) and the United States (*n* = 1, 1.5%). The isolates were recovered from various clinical specimens, including respiratory samples (sputum, broncho-alveolar lavage (BAL) and bronchial wash), nose and nasal sinuses, ear, wounds, pus/abscess, eye, nail, burn, pleural fluid and an unknown culture plate of clinical specimen received for identification from an external facility ([Table 1](#T1){ref-type="table"}).

###### 

Patients demographics, clinical data, antifungal treatment, and *Aspergillus* spp. isolated.

  **Specimen number**   **Gender/age**   **Origin**     **Specimen type**                     **Clinical data**                                                                    **Histopathology/ CT**   **Mortality within 30 days**   **Treatment**                                                              ***Aspergillus* species**
  --------------------- ---------------- -------------- ------------------------------------- ------------------------------------------------------------------------------------ ------------------------ ------------------------------ -------------------------------------------------------------------------- ------------------------------
  Q1444                 M/48             Qatar          Nasal swab                            Nephrotic syndrome, on immunosuppressant, fungal sinusitis                           \+                       Alive                          NA[^a^](#TN1){ref-type="table-fn"}                                         *Aspergillus terreus*
  Q3252                 M/62             KSA            Burn                                  Deep left knee burn                                                                  NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q0098                 M/49             Sudan          Tissue                                TB[^j^](#TN10){ref-type="table-fn"}, pulmonary aspergillosis, aspergilloma, X-ray+   \+                       Alive                          ITC[^b^](#TN2){ref-type="table-fn"}                                        *Aspergillus flavus*
  Q0224                 F/49             KSA            BAL[^g^](#TN7){ref-type="table-fn"}   Endometrial adenocarcinoma                                                           NA                       Alive                          AMB[^c^](#TN3){ref-type="table-fn"}, CAS[^d^](#TN4){ref-type="table-fn"}   *Aspergillus flavus*
  Q4000676              F/29             India          Sinus mucosa                          Nasal polyp, diabetic                                                                \+                       Alive                          NA                                                                         *Aspergillus welwitschiae*
  Q0180                 M/22             Jordan         Nasal swab                            Nasal polyp                                                                          \+                       Alive                          NA                                                                         *Aspergillus flavus*
  Q1013                 M/27             India          Tissue                                skull lesion, sphenoid sinus extending to pteryoid fascia                            NA                       Died                           NA                                                                         *Aspergillus flavus*
  Q0878                 M/23             Qatar          Tissue                                Maxillary ethmoid sinus                                                              NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q8000006              M/17             KSA            BAL                                   Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus sublatus*
  Q0078                 M/60             Pakistan       BW[^h^](#TN8){ref-type="table-fn"}    Pneumonia                                                                            NA                       Alive                          CAS                                                                        *Aspergillus terreus*
  Q0139                 M/21             India          Nasal swab                            Allergic rhinosinusitis                                                              NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q6070                 M/11             Qatar          Wound                                 Fracture (RTA[^k^](#TN11){ref-type="table-fn"})                                      NA                       Alive                          NA                                                                         *Aspergillus citrinoterreus*
  Q1129                 M/43             Pakistan       Debris from nose                      Fungal sinusitis                                                                     NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q0205                 M/22             Nepal          BAL                                   Neutropenia, pancytopenia                                                            --                       Died                           NA                                                                         *Aspergillus nidulans*
  Q0404                 F/33             Pakistan       Tissue                                Fungal sinusitis                                                                     \+                       Alive                          NA                                                                         *Aspergillus welwitschiae*
  Q0782                 F/35             India          Tissue                                Fungal sinusitis                                                                     \+                       Alive                          NA                                                                         *Aspergillus pseudonomius*
  Q0807                 M/6              Pakistan       Tissue                                Chronic granulomatous disease with *Aspergillus* brain abscess                       NA                       Alive                          VCZ[^e^](#TN5){ref-type="table-fn"}+AMB                                    *Aspergillus fumigatus*
  Q6057                 M/48             Egypt          Plate Culture                         Unknown                                                                              NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q1047                 M/27             Bangladesh     Tissue                                fungal sinusitis with intracranial extension                                         NA                       Alive                          VCZ+CAS                                                                    *Aspergillus fumigatus*
  Q1072                 M/13             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus tubingensis*
  Q1332                 M/30             Nepal          Pus aspirate (Brain)                  Fungal sinusitis                                                                     \+                       Alive                          FL[^f^](#TN6){ref-type="table-fn"}, AMB, VCZ, ITC                          *Aspergillus fumigatus*
  Q6746                 M/29             Sudan          Sphenoid sinus swab                   Fungal sinusitis                                                                     \+                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0012                 F/61             UAE            Tissue                                Nasal polyp, breast Ca                                                               --                       Alive                          NA                                                                         *Aspergillus tubingensis*
  Q1374                 M/35             India          Tissue                                Nasal polyp                                                                          NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q0120                 M/52             Sudan          Sputum                                Interstitial lung disease, aspergillosis                                             NA                       Alive                          VCZ                                                                        *Aspergillus fumigatus*
  Q0140                 M/47             Sudan          Wound Tissue                          Brain tumor                                                                          NA                       Died                           CAS, FL, Miconazole, VCZ                                                   *Aspergillus nidulans*
  Q1490                 F/18             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q0338                 M/27             India          Tissue                                fungal sinusitis                                                                     NA                       Alive                          AMB, ITC, VCZ                                                              *Aspergillus flavus*
  Q0334                 F/15             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0416                 F/56             Sudan          Tissue                                fungal sinusitis, CT+                                                                \+                       Alive                          VCZ, ITC                                                                   *Aspergillus welwitschiae*
  Q0521                 F/74             Qatar          Tissue                                RTA                                                                                  NA                       Alive                          AMB                                                                        *Aspergillus tamarii*
  Q0609                 F/36             South Africa   BW                                    Bronchopulmonary Aspergillosis                                                       NA                       Alive                          VCZ                                                                        *Aspergillus fumigatus*
  Q4672                 F/18             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0688                 M/52             Qatar          Pleural Fluid                         Lung Cancer                                                                          NA                       Died                           VCZ                                                                        *Aspergillus fumigatus*
  Q0234A                F/37             Sudan          Tissue                                Fungal sinusitis                                                                     NA                       Alive                          VCZ, ITC                                                                   *Aspergillus welwitschiae*
  Q0234B                F/37             Sudan          Tissue                                Fungal sinusitis                                                                     NA                       Alive                          VCZ, ITC                                                                   *Aspergillus flavus*
  Q0438                 M/80             Tunisia        BAL                                   Lung cancer                                                                          NA                       Died                           NA                                                                         *Aspergillus terreus*
  Q0490                 F/26             Sudan          Tissue                                Fungal sinusitis                                                                     NA                       Alive                          ITC                                                                        *Aspergillus welwitschiae*
  Q7406                 M/4              Qatar          Ear Swab                              Recurrent tonsillitis, otalgia                                                       NA                       Alive                          Miconazole                                                                 *Aspergillus terreus*
  Q0477                 M/66             Pakistan       BAL                                   Interstitial lung disease                                                            NA                       Alive                          NA                                                                         *Aspergillus pallidofulvus*
  Q6630                 F/49             Pakistan       Ear Swab                              ALL[^l^](#TN12){ref-type="table-fn"}                                                 NA                       Alive                          Miconazole                                                                 *Aspergillus chevalieri*
  Q1114                 F/36             India          BAL                                   Aspergillus pneumonia                                                                NA                       Alive                          AMB, CAS, VCZ                                                              *Aspergillus welwitschiae*
  Q0725                 F/39             India          Tissue                                Fungal sinusitis                                                                     NA                       Alive                          VCZ                                                                        *Aspergillus flavus*
  Q4260                 F/49             Sudan          Ear Swab                              Hearing loss                                                                         NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0567                 M/72             Palestine      Exit site swab                        ESRD[^m^](#TN13){ref-type="table-fn"}                                                NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q1177                 M/78             Qatar          BW                                    Chest infiltrate                                                                     NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q1169                 F/44             Qatar          Foot tissue                           Septic shock, diabetic, ESRD, bed sore                                               NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q1165                 F/47             UAE            BAL                                   Lung fibrosis                                                                        NA                       Alive                          VCZ                                                                        *Aspergillus flavus*
  Q6596                 M/63             Qatar          BAL                                   Polyneuropathy                                                                       NA                       Died                           Anidulafungin                                                              *Aspergillus terreus*
  Q1301                 F/25             Qatar          Nail                                  Onychomycosis                                                                        NA                       Alive                          NA                                                                         *Aspergillus quadrilineatus*
  Q6198                 M/32             Jordan         Eye swab                              NA                                                                                   NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q1467                 F/35             Egypt          Nasal swab                            Skull base meningioma                                                                NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q4000006              F/55             Qatar          BW                                    Bronchiolar asthma                                                                   NA                       Alive                          Miconazole                                                                 *Aspergillus terreus*
  Q0518                 M/29             Sri Lanka      Ear                                   ASOM[^n^](#TN14){ref-type="table-fn"}                                                NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q0333                 M/38             Sri Lanka      Tissue                                Nasal polyp                                                                          \+                       Alive                          NA                                                                         *Aspergillus tubingensis*
  Q2266                 F/35             Pakistan       Ethmoid sinus tissue                  Fungal sinusitis                                                                     \+                       Alive                          VCZ, ITC                                                                   *Aspergillus welwitschiae*
  Q6811                 F/8              Qatar          Ear                                   Otomycosis                                                                           NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q1651                 F/18             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q7463                 M/25             India          Ear                                   Ear pain                                                                             NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q7675                 21/F             Qatar          Sputum                                Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q1787                 M/28             Jordan         Ethmoid sinus tissue                  Fungal sinusitis                                                                     \+                       Alive                          ITC                                                                        *Aspergillus citrinoterreus*
  Q2779                 M/79             Qatar          Sputum                                COPD[^o^](#TN15){ref-type="table-fn"}, lung fibrosis                                 NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0486                 M/40             India          BAL                                   TB                                                                                   NA                       Alive                          NA                                                                         *Aspergillus caespitosus*
  Q3118                 M/60             Qatar          Ear                                   Chronic kidney disease                                                               NA                       Alive                          NA                                                                         *Aspergillus flavus*
  Q0700                 M/6              Qatar          BAL                                   Cystic fibrosis                                                                      NA                       Alive                          NA                                                                         *Aspergillus fumigatus*
  Q3996                 F/74             Syria          Ear                                   Sensorineural hearing loss since birth                                               NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q4145                 M/42             Nepal          Sputum                                RTA                                                                                  NA                       Alive                          NA                                                                         *Aspergillus terreus*
  Q0861                 F/39             Sudan          BAL                                   Chronic cough                                                                        NA                       Alive                          ITC                                                                        *Aspergillus flavus*
  Q5260                 M/57             Sudan          ETT[^i^](#TN9){ref-type="table-fn"}   Colitis, Pleural effusion                                                            NA                       Died                           NA                                                                         *Aspergillus citrinoterreus*
  Q5254                 F/48             USA            Sputum                                URTI[^p^](#TN16){ref-type="table-fn"}                                                NA                       Alive                          NA                                                                         *Aspergillus flavus*

*Data not Available*.

*Itraconazole*.

*Amphotericin B*.

*Caspofungin*.

*Voriconazole*.

*Fluconazole*.

*Broncho-Alveolar Lavage*.

*Bronchial Wash*.

*Endotracheal Tube secretion*.

*Tuberculosis*.

*Road Traffic Accident*.

*Acute Lymphoblastic Leukemia*.

*End Stage Renal Disease*.

*Acute Suppurative Otitis Media*.

*Chronic Obstructive Pulmonary Disease*.

*Upper Respiratory Tract Infection*.

*+, Positive; --, Negative; CT, Computed Tomography*.

Isolation and Identification
----------------------------

*Aspergillus species* were identified by macro and microscopy according to the laboratory standard operative protocol of the microbiology laboratory at Hamad general hospital in Qatar. Specimens were cultured on Sabouraud dextrose agar (SDA; Difco Laboratories, Detroit, MI) with and without chloramphenicol. Culture plates were incubated at 26 and 37°C and were observed daily for growth up to 10 days. Direct microscopy from clinical specimens was performed using Blankophor P fluorescent stain (Bayer AG, Germany). Cultures were preserved at −70°C using cryo-tubes (Mast Diagnostics, Bootle, Merseyside, UK) until further use.

Molecular Identification
------------------------

### DNA Extraction

Genomic DNA was extracted as described by Bolano et al. ([@B12]), with minor modifications. In short, *Aspergillus* biomass, which was grown on oatmeal agar (OA; home-made at Westerdijk Institute) for 5 days, was bead-beaten with sterile sand, 750 μl of lysis buffer, and 750 μl of phenol-chloroform in 2 ml screw-capped tube. The mixture was centrifuged and the supernatant was transferred to 1.5 ml Eppendorf\'s tube with an equal amount of ice-cold 96% ethanol. One hundred microliter of 3.0 M ice-cold sodium acetate was added, mixed gently, and stored at −20°C for 30--60 min. The mixture was then centrifuged at 4°C. The DNA pellet was air-dried and re-suspended in 100 μl Tris Ethylenediaminetetraacetic acid (TE) buffer. The solution was incubated successively at 37 and 65°C both for 10 min, and stored at −20°C. The DNA quality was checked by 1.5% agarose gel electrophoresis.

### PCR and Sequencing

For identification of the isolates, two loci were amplified, namely β-tubulin (*BenA*), and calmodulin (*CaM*). A segment of the β-tubulin gene was amplified using primers Bt2a (5′-GGTAACCAAATCGGTGCTGCTTTC-3′) and Bt2b (5′-ACCCTCAGTGTAGTGACCCTTGGC-3′) (Glass and Donaldson, [@B34]), and a fragment of the calmodulin gene was amplified using primers cmd5 (5′-CCGAGTACAAGGAGGCCTTC-3′) and cmd6 (5′-CCGATAGAGGTCATAACGTGG-3′) (Hong et al., [@B41]). The amplification of *BenA* and *CaM* loci for some of our strains resulted in poor sequence data and these strains were identified by at least one gene (*BenA* or *CaM)*. Each PCR mixture (final volume 24 μl) contained 16.45 μl water, 0.75 μl (50 mM) Magnesium chloride, 2.5 μl 10 × PCR buffer, 1.95 μl dNTP mix (1 mM), 1.25 μl dimethyl sulfoxide (DMSO), 0.5 μl of each primer (10 μM), 0.1 μl Taq polymerase (BioTaq 5 U/μL), and 1 μl of template DNA.

The PCR and sequencing reactions were performed as described previously (Visagie et al., [@B100]). Sequences were identified using the Basic Local Alignment Search Tool (BLAST) of The NCBI database (NCBI, [@B68]). A Westerdijk Institute in-house database with the latest taxonomic names and additions was also used for identification. The sequences were then deposited to the GenBank database and accession numbers are presented in [Table 2](#T2){ref-type="table"}.

###### 

*Aspergillus* spp. isolates with Genbank accession numbers.

  **Accession number**   ***Aspergillus* spp**.         **Genbank accession number**   
  ---------------------- ------------------------------ ------------------------------ ----------------------
  [Q0098](Q0098)         *Aspergillus flavus*           [MK159746](MK159746)           [MK039842](MK039842)
  [Q0782](Q0782)         *Aspergillus pseudonomius*     [MK159747](MK159747)           [MK039858](MK039858)
  [Q0521](Q0521)         *Aspergillus tamarii*          [MK159748](MK159748)           [MK039859](MK039859)
  [Q0477](Q0477)         *Aspergillus pallidofulvus*    [MK159749](MK159749)           [MK039839](MK039839)
  [Q0224](Q0224)         *Aspergillus flavus*           [MK159750](MK159750)           [MK039851](MK039851)
  [Q1013](Q1013)         *Aspergillus flavus*           [MK159751](MK159751)           [MK039852](MK039852)
  [Q1129](Q1129)         *Aspergillus flavus*           [MK159752](MK159752)           [MK039848](MK039848)
  [Q3118](Q3118)         *Aspergillus flavus*           [MK159753](MK159753)           [MK039855](MK039855)
  [Q1374](Q1374)         *Aspergillus flavus*           [MK159754](MK159754)           [MK039843](MK039843)
  [Q5254](Q5254)         *Aspergillus flavus*           [MK159755](MK159755)           --
  [Q1165](Q1165)         *Aspergillus flavus*           [MK159756](MK159756)           [MK039853](MK039853)
  [Q6198](Q6198)         *Aspergillus flavus*           [MK159757](MK159757)           [MK039856](MK039856)
  [Q0234B](Q0234B)       *Aspergillus flavus*           [MK159758](MK159758)           [MK039845](MK039845)
  [Q1169](Q1169)         *Aspergillus flavus*           [MK159759](MK159759)           [MK039846](MK039846)
  [Q0338](Q0338)         *Aspergillus flavus*           [MK159760](MK159760)           [MK039857](MK039857)
  [Q0139](Q0139)         *Aspergillus flavus*           [MK159761](MK159761)           [MK039847](MK039847)
  [Q0861](Q0861)         *Aspergillus flavus*           [MK159762](MK159762)           [MK039854](MK039854)
  [Q3252](Q3252)         *Aspergillus flavus*           [MK159763](MK159763)           [MK039844](MK039844)
  [Q0725](Q0725)         *Aspergillus flavus*           [MK159764](MK159764)           [MK039849](MK039849)
  [Q0012](Q0012)         *Aspergillus tubingensis*      [MK159765](MK159765)           [MK039893](MK039893)
  [Q1072](Q1072)         *Aspergillus tubingensis*      [MK159766](MK159766)           [MK039894](MK039894)
  [Q0333](Q0333)         *Aspergillus tubingensis*      [MK159767](MK159767)           [MK039895](MK039895)
  [Q0416](Q0416)         *Aspergillus welwitschiae*     [MK159768](MK159768)           [MK039898](MK039898)
  [Q0490](Q0490)         *Aspergillus welwitschiae*     [MK159769](MK159769)           [MK039901](MK039901)
  [Q1114](Q1114)         *Aspergillus welwitschiae*     [MK159770](MK159770)           [MK039902](MK039902)
  [Q2266](Q2266)         *Aspergillus welwitschiae*     [MK159771](MK159771)           [MK039899](MK039899)
  [Q4000676](Q4000676)   *Aspergillus welwitschiae*     [MK159772](MK159772)           [MK039900](MK039900)
  [Q8000006](Q8000006)   *Aspergillus sublatus*         [MK159773](MK159773)           [MK039904](MK039904)
  [Q1301](Q1301)         *Aspergillus quadrilineatus*   [MK159774](MK159774)           [MK039905](MK039905)
  [Q0140](Q0140)         *Aspergillus nidulans*         [MK159775](MK159775)           [MK039906](MK039906)
  [Q0486](Q0486)         *Aspergillus caespitosus*      --                             [MK039903](MK039903)
  [Q6630](Q6630)         *Aspergillus chevalieri*       [MK159776](MK159776)           [MK039892](MK039892)
  [Q0078](Q0078)         *Aspergillus terreus*          [MK159777](MK159777)           [MK039860](MK039860)
  [Q1467](Q1467)         *Aspergillus terreus*          [MK159778](MK159778)           [MK039875](MK039875)
  [Q2779](Q2779)         *Aspergillus terreus*          [MK159779](MK159779)           [MK039863](MK039863)
  [Q6596](Q6596)         *Aspergillus terreus*          [MK159780](MK159780)           [MK039869](MK039869)
  [Q4000006](Q4000006)   *Aspergillus terreus*          [MK159781](MK159781)           [MK039866](MK039866)
  [Q4145](Q4145)         *Aspergillus terreus*          [MK159782](MK159782)           [MK039868](MK039868)
  [Q3996](Q3996)         *Aspergillus terreus*          [MK159783](MK159783)           [MK039864](MK039864)
  [Q6746](Q6746)         *Aspergillus terreus*          [MK159784](MK159784)           [MK039874](MK039874)
  [Q4260](Q4260)         *Aspergillus terreus*          [MK159785](MK159785)           [MK039867](MK039867)
  [Q6811](Q6811)         *Aspergillus terreus*          [MK159786](MK159786)           [MK039872](MK039872)
  [Q7406](Q7406)         *Aspergillus terreus*          [MK159787](MK159787)           [MK039876](MK039876)
  [Q4672](Q4672)         *Aspergillus terreus*          --                             [MK039873](MK039873)
  [Q1651](Q1651)         *Aspergillus terreus*          [MK159788](MK159788)           [MK039870](MK039870)
  [Q7463](Q7463)         *Aspergillus terreus*          [MK159789](MK159789)           [MK039865](MK039865)
  [Q1444](Q1444)         *Aspergillus terreus*          --                             [MK039862](MK039862)
  [Q1787](Q1787)         *Aspergillus citrinoterreus*   [MK159790](MK159790)           [MK039877](MK039877)
  [Q5260](Q5260)         *Aspergillus citrinoterreus*   [MK159791](MK159791)           [MK039878](MK039878)
  [Q0120](Q0120)         *Aspergillus fumigatus*        [MK159792](MK159792)           [MK039880](MK039880)
  [Q0567](Q0567)         *Aspergillus fumigatus*        [MK159793](MK159793)           [MK039881](MK039881)
  [Q6057](Q6057)         *Aspergillus fumigatus*        [MK159794](MK159794)           [MK039891](MK039891)
  [Q0609](Q0609)         *Aspergillus fumigatus*        [MK159795](MK159795)           [MK039882](MK039882)
  [Q1177](Q1177)         *Aspergillus fumigatus*        [MK159796](MK159796)           [MK039886](MK039886)
  [Q1490](Q1490)         *Aspergillus fumigatus*        [MK159797](MK159797)           [MK039885](MK039885)
  [Q7675](Q7675)         *Aspergillus fumigatus*        [MK159798](MK159798)           [MK039890](MK039890)
  [Q0700](Q0700)         *Aspergillus fumigatus*        [MK159799](MK159799)           [MK039889](MK039889)
  [Q1047](Q1047)         *Aspergillus fumigatus*        [MK159800](MK159800)           [MK039888](MK039888)
  [Q0807](Q0807)         *Aspergillus fumigatus*        [MK159801](MK159801)           [MK039887](MK039887)
  [Q1332](Q1332)         *Aspergillus fumigatus*        [MK159802](MK159802)           [MK039884](MK039884)
  [Q0688](Q0688)         *Aspergillus fumigatus*        [MK159803](MK159803)           [MK039883](MK039883)
  [Q0518](Q0518)         *Aspergillus flavus*           --                             [MK039840](MK039840)
  [Q0878](Q0878)         *Aspergillus flavus*           --                             [MK039841](MK039841)
  [Q0180](Q0180)         *Aspergillus flavus*           --                             [MK039850](MK039850)
  [Q0334](Q0334)         *Aspergillus terreus*          --                             [MK039861](MK039861)
  [Q0438](Q0438)         *Aspergillus terreus*          --                             [MK039871](MK039871)
  [Q6070](Q6070)         *Aspergillus citrinoterreus*   --                             [MK039879](MK039879)
  [Q0234A](Q0234A)       *Aspergillus welwitschiae*     --                             [MK039896](MK039896)
  [Q0404](Q0404)         *Aspergillus welwitschiae*     --                             [MK039897](MK039897)
  [Q0205](Q0205)         *Aspergillus nidulans*         --                             [MK039907](MK039907)

### Antifungal Susceptibility

*In vitro* antifungal susceptibility testing was performed according to the CLSI M38-A2 microbroth dilution method for filamentous fungi (Clinical and Laboratory Standards Institute \[CLSI\], [@B23]). The antifungal agents tested were: amphotericin B (AMB), voriconazole (VRC), itraconazole (ITC), posaconazole (PCZ) (Sigma-Aldrich, St. Louis, MO, USA), isavuconazole (ISA; Basilea Pharmaceutica, Basel, Switzerland), anidulafungin (ANID; Pfizer Pharma), and micafungin (MICA; Astellas Pharma Inc.). All antifungal drugs were tested in concentrations ranging from 0.03 to 16 μg/ml. *Pichia kudriavzevii* (*Candida krusei*) (ATCC 6258) was used as a quality control (QC) strain as indicated in CLSI M38-A2. In addition, we tested *Aspergillus fumigatus* (ATCC 46645), a reference strain from an official culture collection with known stable MIC values. The susceptibility plates were prepared and stored at −70°C until use. Results were read after 24 and 48 h of incubation at 37°C. The minimum inhibitory concentrations (MICs) for AMB and azoles were determined as the lowest concentration of the antifungal drug that prevents any discernable growth (100% inhibition) whereas the minimum effective concentrations (MECs) for echinocandins were defined as the lowest concentration of the antifungal drug that leads to rounded compact hyphal growth compared with the unchanged growth in the control well. Visual reading of the MICs/MECs was performed with the aid of an inverted mirror (Clinical and Laboratory Standards Institute \[CLSI\], [@B23]).

*Aspergillus* MICs were analyzed using the latest epidemiological cut-off values (ECVs) proposed by CLSI (Clinical and Laboratory Standards Institute \[CLSI\], [@B24]) to determine the presence of wild type (WT) and non-wild type (NWT) strains.

Results {#s3}
=======

Patients Groups and Aspergillosis
---------------------------------

Seventy *Aspergillus* strains were isolated from clinical specimens obtained from 67 patients including 40 males and 27 females. The age of female and male patients ranged from 8 to 74 (media *n* = 36) and 4 to 80 (media *n* = 36.5) years old, respectively. Eight patients were under 18 years (17, 15, 13, 11, 8, 4, and 2 patients were 6 years old) and 50% (4/8) of them suffered from cystic fibrosis ([Table 1](#T1){ref-type="table"}).

The majority of *Aspergillus* species were isolated from respiratory specimens (*n* = 28, 40%) and nasal sinuses (*n* = 24, 34.3%) ([Table 3](#T3){ref-type="table"}). Two isolates (*A. welwitschiae* and *A. flavus*) were recovered from a patient with fungal rhinosinusitis. Three strains (1 *A. fumigatus* and 2 *A. terreus*) were isolated separately from sputum samples of a patient with cystic fibrosis with 4 months interval between isolations.

###### 

Occurrence of *Aspergillus* spp. in clinical specimens.

                                **Respiratory**   **Fungal sinusitis**   **Wound**   **Ear**   **Brain abscess**   **Nail**   **Burn**   **Eye**   **Unknown**
  ----------------------------- ----------------- ---------------------- ----------- --------- ------------------- ---------- ---------- --------- -------------
  *A. flavus (n = 19)*          5                 9                      1           2                                        1          1         
  *A. terreus (n = 17)*         9                 3                                  5                                                             
  *A. fumigatus(n = 12)*        7                 1                      1                     2                                                   1
  *A. welwitschiae (n = 7)*     1                 6                                                                                                
  *A. citrinoterreus (n = 3)*   1                 1                      1                                                                         
  *A. tubingenesis (n = 3)*     1                 2                                                                                                
  *A. nidulans (n = 2)*         1                                        1                                                                         
  *A. pseudonomius (n = 1)*                       1                                                                                                
  *A. chevalieri (n = 1)*                                                            1                                                             
  *A. tamarii (n = 1)*                                                   1                                                                         
  *A. sublatus (n = 1)*         1                                                                                                                  
  *A. quadrilineatus (n = 1)*                                                                                      1                               
  *A. pallidofulvus (n = 1)*    1                                                                                                                  
  *A. caespitosus (n = 1)*      1                                                                                                                  
  Total (*n* = 70)              28                23                     5           8         2                   1          1          1         1

Fourteen patients (20.9%) presented with IA and 55 patients with non-invasive infections. The underlying conditions of these patients were immune suppression (cancer, on immunosuppressant drugs, and diabetes), chronic pulmonary disease (tuberculosis and cystic fibrosis), pneumonia, rhinosinusitis, and onychomycosis, in addition to ear, wound, skin, and eye infections. Seventeen patients were immunocompromised (24.3%) and seven patients (10.4%) died within 30 days of diagnosis irrespective of antifungal treatment. Two of the deceased patients were infected with *Aspergilus terreus*, 2 with *Aspergillus nidulans*, and 3 patients each with *Aspergillus citrinoterreus, A. flavus*, and *A. fumigatus*, respectively. Patients\' demographics, clinical information and *Aspergillus* species isolated are listed in [Table 1](#T1){ref-type="table"}.

Fourteen *Aspergillus* species belonging to seven sections were recovered ([Table 1](#T1){ref-type="table"}). In addition, we detected cryptic *Aspergillus* species in 29% of our isolates (*n* = 20) which belong to 6 species complexes namely *A. welwitschiae* (*n* = 7, 10%) (section *Nigri*), *Aspergillus tubingensis* (*n* = 3, 4.3%) (section *Nigri*), *A. citrinoterreus* (*n* = 3, 4.3%) (section *Terrei*), *A. pseudonomius* (*n* = 1, 1.4%) (section *Flavi*), *Aspergillus chevalieri* (*n* = 1, 1.4%) (section *Aspergillus*)*, A. sublatus* (1.4%) (section *Nidulantes*)*, Aspergillus quadrilineatus* (1.4%) (section *Nidulantes*)*, Aspergillus pallidofulvus* (1.4%) (section *Circumdati*), *Aspergillus tamarii* (1.4%) (section *Flavi*) and *Aspergillus caespitosus* (1.4%) (section *Nidulantes*).

*A. welwitschiae* was the most isolated cryptic species (*n* = 7, 35%), followed by *A. tubingensis* and *A. citrinoterreus* (each *n* = 3, 15%) *A. terreus* was isolated from 62.5% (5/8) of the ear specimens and 47.4% (9/19) of *A. flavus* isolates were recovered from patients presented with fungal rhinosinusitis.

Antifungal Susceptibility
-------------------------

All the MICs were within the required ranges for the QC and reference strains tested. Since there are no Clinical Break Points (CBPs) available for *Aspergillus* spp. by the CLSI, MIC data were analyzed and interpreted according to the ECVs indicated in the CLSI M59-ED2 (Clinical and Laboratory Standards Institute \[CLSI\], [@B24]). There are neither CPBs nor ECVs available for ANID and MICA.

One isolate of *A. fumigatus* showed a MIC of 2.0 μg/ml for ITC and was therefore categorized as NWT (ECV = 1). Another *A. fumigatus* strain exhibited high MEC values for ANID and MICA (4 and 16 μg/ml, respectively). One *A. flavus* showed an elevated MIC of 16 μg/ml for AMB and was considered to be NWT (ECV = 4). All *A. nidulans* isolated (*n* = 2) had elevated MICs of 2.0 μg/ml to AMB. Antifungal susceptibilities were not determined for *A. chevalieri* since it repeatedly failed to grow in the susceptibility test medium. The antifungal susceptibility data are presented in [Table 4](#T4){ref-type="table"}.

###### 

*In vitro* antifungal susceptibility results of *Aspergillus* spp.

  ***Aspergillus* spp. isolated (*n*)**   **Antifungal**   **Range**     **GM**   **MIC/MEC (μg/ml)**                                    
  --------------------------------------- ---------------- ------------- -------- --------------------- --- ---- --- --- --- --- --- --- ---
  *A. flavus (19)*                        ITC              0.03--0.25    0.15     1                     1   11   6                       
                                          AMB              0.125--16     0.66                               2    1   6   7   2           1
                                          PCZ              0.03--0.25    0.06     10                    4   4    1                       
                                          VCZ              0.03--0.25    0.17     1                     2   4    9   3                   
                                          ISA              0.03--1       0.07     11                    4   2        1   1               
                                          ANID             0.03          0.03     19                                                     
                                          MICA             0.03          0.03     19                                                     
  *A. terreus (17)*                       ITC              0.03--0.125   0.07     3                     7   7                            
                                          AMB              0.25--16      0.92                                    2   8   3   2       1   1
                                          PCZ              0.03--0.06    0.04     13                    4                                
                                          VCZ              0.06--0.25    0.14                           4   7    5   1                   
                                          ISA              0.03--0.25    0.04     15                    1        1                       
                                          ANID             0.03          0.03     17                                                     
                                          MICA             0.03          0.03     17                                                     
  *A. fumigatus (12)*                     ITC              0.03--2       0.22     1                         4    5       1   1           
                                          AMB              0.125--2      0.53                               1    4   1   5   1           
                                          PCZ              0.03--0.25    0.06     5                     3   3    1                       
                                          VCZ              0.06--1       0.17                           2   7    1       2               
                                          ISA              0.03--0.25    0.09     5                     1        6                       
                                          ANID             0.03--4       0.05     11                                             1       
                                          MICA             0.03--16      0.05     11                                                     1
  *A. welwitschiae (7)*                   ITC              0.25--0.5     0.37                                    3   4                   
                                          AMB              0.25          0.25                                    7                       
                                          PCZ              0.06          0.06                           7                                
                                          VCZ              0.25--0.5     0.30                                    5   2                   
                                          ISA              0.06--025     0.11                           2   4    1                       
                                          ANID             0.03          0.03                           7                                
                                          MICA             0.03          0.03                           7                                
  *A. tubingensis (3)*                    ITC              1             1.00                                            3               
                                          AMB              0.25--0.5     0.40                                    1   2                   
                                          PCZ              0.125--0.5    0.25                               1    1   1                   
                                          VCZ              0.5           0.50                                        3                   
                                          ISA              0.5--2        1.00                                    1           2           
                                          ANID             0.03          0.03     3                                                      
                                          MICA             0.03          0.03     3                                                      
  *A. citrinoterreus (3)*                 ITC              0.03--0.6     0.04     2                     1                                
                                          AMB              1--2          1.26                                            2   1           
                                          PCZ              0.03          0.03     3                                                      
                                          VCZ              0.06--0.125   0.10                           1   2                            
                                          ISA              0.03          0.03     3                                                      
                                          ANID             0.03          0.03     3                                                      
                                          MICA             0.03          0.03     3                                                      
  *A. nidulans (2)*                       ITC              0.125                                            2                            
                                          AMB              2                                                                 2           
                                          PCZ              0.03--0.125            1                         1                            
                                          VCZ              0.03          0.03     2                                                      
                                          ISA              0.03          0.03     2                                                      
                                          ANID             0.03          0.03     2                                                      
                                          MICA             0.03          0.03     2                                                      
  *A. sublatus (1)*                       ITC              --            --                                 1                            
                                          AMB              --            --                                          1                   
                                          PCZ              --            --                                          1                   
                                          VCZ              --            --                                 1                            
                                          ISA              --            --                                      1                       
                                          ANID             --            --                                 1                            
                                          MICA             --            --                                      1                       
  *A. pseudonomius (1)*                   ITC              --            --                                      1                       
                                          AMB              --            --                                              1               
                                          PCZ              --            --                                 1                            
                                          VCZ              --            --                                      1                       
                                          ISA              --            --                             1                                
                                          ANID             --            --       1                                                      
                                          MICA             --            --       1                                                      
  *A. tamarii (1)*                        ITC              --            --                             1                                
                                          AMB              --            --                                      1                       
                                          PCZ              --            --                             1                                
                                          VCZ              --            --                                      1                       
                                          ISA              --            --       1                                                      
                                          ANID             --            --       1                                                      
                                          MICA             --            --       1                                                      
  *A. pallidofulvus (1)*                  ITC              --            --                                      1                       
                                          AMB              --            --                                                  1           
                                          PCZ              --            --                                      1                       
                                          VCZ              --            --                                      1                       
                                          ISA              --            --                                      1                       
                                          ANID             --            --       1                                                      
                                          MICA             --            --       1                                                      
  *A. quadrilineatus(1)*                  ITC              --            --                                      1                       
                                          AMB              --            --                                              1               
                                          PCZ              --            --                             1                                
                                          VCZ              --            --                                      1                       
                                          ISA              --            --       1                                                      
                                          ANID             --            --       1                                                      
                                          MICA             --            --       1                                                      
  *A. caespitosus(1)*                     ITC              --            --                             1                                
                                          AMB              --            --                                              1               
                                          PCZ              --            --       1                                                      
                                          VCZ              --            --       1                                                      
                                          ISA              --            --       1                                                      
                                          ANID             --            --       1                                                      
                                          MICA             --            --       1                                                      

*ITC, Itraconazole; AMB, Amphotericin B; PCZ, Posaconazole; VCZ, Voriconazole; ISA, Isavuconazole; ANID, Anidulafungin; MICA, Micafungin*.

For all *Aspergillus* isolates, the range of MICs/MECs for triazoles, AMB, and echinocandins were: ITC (0.03--2.0 μg/ml), PCZ (0.03--0.5 μg/ml), VRC (0.03--1 μg/ml), ISA (0.03--2.0 μg/ml), AMB (0.125--16 μg/ml), ANID (0.03--4.0 μg/ml) and MICA (0.03--16 μg/ml). The overall geometric mean (GM), MIC~50~ and MIC~90~ are listed in [Table 5](#T5){ref-type="table"}.

###### 

Geometric mean (GM), MIC/MEC~50/90~, range and median of *Aspergillus* MICs.

                **ITC**   **AMB**     **PCZ**     **VCZ**   **ISA**   **ANID**   **MICA**
  ------------- --------- ----------- ----------- --------- --------- ---------- ----------
  GM            0.15      0.68        0.06        0.17      0.06      0.03       0.03
  MIC/MEC~50~   0.125     0.5         0.06        0.25      0.03      0.03       0.03
  MIC/MEC~90~   0.5       2           0.125       0.5       0.25      0.03       0.03
  Range         0.03--2   0.125--16   0.03--0.5   0.03--1   0.03--2   0.03--4    0.03--16
  Median        0.125     0.5         0.06        0.25      0.03      0.03       0.03

*ITC, Itraconazole; AMB, Amphotericin B; PCZ, Posaconazole; VRC, Voriconazole; ISA, Isavuconazole; ANID, Anidulafungin; MICA, Micafungin; GM, Geometric mean*.

Discussion {#s4}
==========

The present study describes the molecular identification and susceptibility patterns of 70 *Aspergillus* strains isolated from clinical specimens of 67 patients from Hamad general hospital in Qatar, including adults (88%) and pediatric patients (12%). To our knowledge, this is considered as the first study exploring the molecular identification and antifungal susceptibility profiles of clinical aspergilli in this country.

Twenty isolates (29%) of cryptic *Aspergillus* spp. were recovered from patients\' samples representing 10 different species that belong to six sections. Previous studies from Spain and Brazil reported a prevalence of 14.5% (Alastruey-Izquierdo et al., [@B6]) and 19% (Negri et al., [@B69]) for cryptic *Aspergillus* spp., respectively, which is lower than what we found in the current study. The majority of the cryptic species isolated in this study were members of section *Nigri* (*n* = 10/20, 50%). No cryptic species were isolated from section *Fumigati*.

*Aspergillus pseudonomius* is reported in the current study for the first time ever from clinical specimens and was isolated from a patient with fungal rhinosinusitis proven by histopathology. It exhibited low MIC values for all the antifungal drugs tested ([Table 4](#T4){ref-type="table"}). Echinocandins were the most active drugs (MEC = 0.03 μg/ml) and ISA was the most active triazole drug against *A. pseudonomius* with a MIC of 0.06 μg/ml.

In addition, we report the first isolation of *A. welwitschiae* from six patients with fungal rhinosinusitis, three of them were proven by histopathology and one by computed tomography (CT) as invasive infections. *A. welwitschiae* was previously isolated from patients with respiratory infections (Pinto et al., [@B77]) and onychomycosis (Tsang et al., [@B95]). Low MICs were observed for all of the antifungal agents investigated and PCZ was the most active triazole with a MIC of 0.06 μg/ml. *A. welwitschiae* was also isolated in our study from a BAL of a patient with *Aspergillus* pneumonia.

Invasive infections caused by *A. sublatus* were previously reported from patients with HSCT (de Fontbrune et al., [@B25]; Chrenkova et al., [@B22]). Here we report it for the first time from BAL specimen of an adult cystic fibrosis patient with moderate obstructive pulmonary disease. However, we were unable to discern between colonization and infection caused by *A. sublatus*. Echinocandins MICs were relatively higher for *A. sublatus* compared to the other *Aspergillus* spp. in our set, with MIC values of 0.125 and 0.25 μg/ml for ANID and MICA, respectively. Previously reported MICs of ANID and MICA for *A. sublatus* were \<0.0312 μg/ml (Chrenkova et al., [@B22]) which is lower than our findings. ITC and voriconazole were the most active triazoles with MICs of 0.125 μg/ml for both drugs ([Table 4](#T4){ref-type="table"}). *A. sublatus* belongs to *Aspergillus* section *Nidulantes* and is very closely related to *A. quadrilineatus* (Hubka et al., [@B43]). These species are indistinguishable by sequencing *BenA* alone (Hubka et al., [@B43]), whereas reliable identification can be achieved by sequencing *CaM* gene (Hubka et al., [@B43]). In our case, we identified *A. sublatus* by sequencing both *BenA* and *CaM* genes. AMB exhibited low MIC (0.5 μg/ml) in comparison to *A. nidulans* (2.0 μg/ml) which is known to be resistant to AMB (Van\'t Hek et al., [@B98]; Kontoyiannis et al., [@B49]; Bowman et al., [@B13]). A low AMB MIC was also reported in other studies for *A. sublatus* (de Fontbrune et al., [@B25]; Chrenkova et al., [@B22]).

*Aspergillus pallidofulvus* was isolated in the present study from a BAL sample of a patient with interstitial lung disease, which is considered as the second report of this species from clinical specimens after a previous report from India where it was isolated from a BAL sample of a patient with invasive pulmonary aspergillosis (IPA) (Masih et al., [@B62]). The single strain isolated in the current study showed a high MIC value for AMB (2 μg/ml), which was also observed previously for this species (Masih et al., [@B62]). With the available data, it was not possible to recognize *A. pallidofulvus* as the cause of infection or colonization.

The recently described *A. citrinoterreus*, which belongs to section *Terrei*, was reported mainly from patients with respiratory infections, in addition to wound, abscess, nail and sinus infections (Guinea et al., [@B36]; Imbert et al., [@B44]; Vaezi et al., [@B97]). In a global study of 498 strains of *A. terreus* and phenotypically related species, 6 different species of section *Terrei* were identified and *A. citrinoterreus* was the second most isolated species (8.4%) (Zoran et al., [@B104]). In our case, among 20 strains of members of section *Terrei*, 3 strains (15%) were identified as *A. citrinoterreus*. We report the second isolation of this species from a case of fungal rhinosinusitis which was proven by histology. This patient was treated with ITC which exhibited a low *in vitro* MIC of 0.03 μg/ml and for AMB 1 μg/ml. However, there were no data available regarding the therapeutic outcome. The second isolate of *A. citrinoterreus* was from an endotracheal secretion of a patient with colitis and pleural effusion, with no other details about the underlying diseases or the immune status. Antifungal therapy information was not available for this patient who died few days after sample collection, and low MICs were observed ([Table 4](#T4){ref-type="table"}) for all the tested drugs including AMB MIC of 1 μg/ml. The third case of *A. citrinoterreus* was from a wound sample of a patient who had a road traffic accident. Antifungal therapy details were not available and the isolate showed low MICs *in vitro* except for AMB which showed an elevated MIC of 2 μg/ml. It was not possible to categorize the later 2 cases as infection or colonization.

*Aspergillus tamarii* is rarely encountered as a human pathogen. It was reported from few cases of cutaneous aspergillosis (Sharma et al., [@B85]; Kimura et al., [@B48]), onychomycosis (Kristensen et al., [@B54]), burn wound (Renner et al., [@B80]), keratitis (Kredics et al., [@B51]), respiratory (Castro et al., [@B15]) and sinus infections (Paludetti et al., [@B74]). In the current study, we report the isolation of *A. tamarii* from wound tissue of a patient who experienced a road traffic accident. This patient received AMB with unknown treatment outcome and the *in vitro* MIC of AMB was 0.25 μg/ml. We could not determine whether *Aspergillus tamarii* was the cause of infection or a colonizer.

*Aspergillus chevalieri* is one of the most common species present in indoor environments (Hubka et al., [@B42]). Clinically, it has been recovered from a case of cutaneous aspergillosis (Naidu and Singh, [@B67]), a fatal cerebral aspergillosis case (Masih et al., [@B62]), and respiratory, corneal and sinus infections (Siqueira et al., [@B86]). In our study, we isolated *A. chevalieri* from an ear swab of a patient with acute lymphoblastic leukemia (ALL). The patient received miconazole, a topical antifungal drug.

*Aspergillus tubingensis* was found to be a major fungus associated with bronchial colonization in patients with lung disease (Reynaud-Gaubert et al., [@B81]). Previous reports of *A. tubingensis* were from patients with cutaneous aspergillosis (Balajee et al., [@B8]; Pagiotti et al., [@B72]), otomycosis (Szigeti et al., [@B89],[@B90]), keratitis (Dóczi et al., [@B26]), onychomycosis (Nouripour-Sisakht et al., [@B71]), and osteomyelitis (Hedayati et al., [@B40]). We recovered *A. tubingensis* from three patients: one with unknown underlying diseases presented with fungal rhinosinusitis and was proven by histopathology. The second patient suffered from breast cancer and presented with rhinosinusitis. It was considered as either colonization or the allergic type of *Aspergillus* rhinosinusitis due to the negative histology investigation. The third patient had cystic fibrosis with unknown status of invasion or colonization. The antifungal therapy data were unavailable for those patients. In general, low antifungal MICs were exhibited for *A. tubingensis* strains except for ISA which showed high MIC of 2.0 μg/ml for the first and the second cases. No *A. niger sensu stricto* was isolated in our set of strains.

Invasive aspergillosis caused by *A. quadrilineatus*, which is closely related to *A. nidulans*, was previously reported from 2 patients who presented with fungal rhinosinusitis and had undergone bone marrow transplantation for hematological malignancy (Polacheck et al., [@B78]; Drakos et al., [@B27]), three cases of IPA in patients with CGD (Verweij et al., [@B99]), a patient with cerebral aspergillosis (Verweij et al., [@B99]) and another with onychomycosis (Gugnani et al., [@B35]). Our isolate was recovered from a case of onychomycosis, however, it was not possible to confirm that *A. quadrilineatus* was the direct cause of infection or colonization. A lower MIC value for AMB was observed (1 μg/ml) in comparison to *A. nidulans* (2 μg/ml) which is in agreement with a previous report (Verweij et al., [@B99]).

*Aspergillus caespitosus* is a soil fungus (Raper and Thoms, [@B79]; Chen et al., [@B19]) and has not been reported previously as a human pathogen. In the current study, it was isolated from a BAL specimen of a patient suffering from tuberculosis and showed low MICs for all the antifungal drugs tested. It was unknown whether *A. caespitosus* was the cause of true infection or colonization.

*Aspergillus fumigatus* has been reported as the most prevalent species causing IA in different parts of the world, including the United States, Europe and Brazil (Balajee et al., [@B8]; Alastruey-Izquierdo et al., [@B6]; Negri et al., [@B69]). In this study, *A. flavus* was the most prevalent species (27%), which is consistent with reports from India (47%) (Xess et al., [@B102]), Iran (75%) (Zanganeh et al., [@B103]), and Tunisia (79%) (Hadrich et al., [@B39]). The predominance of *A. flavus* in these parts of the world is attributed to arid and semi-arid climates (Kameswaran et al., [@B47]; Hedayati et al., [@B40]). The second most prevalent species in our set was *A. terreus* (24%), followed by *A. fumigatus* (17%). This could be due to ecological preferences for environments specific to Qatar, such as the highly arid deserts, which needs to be investigated thoroughly by an environmental sampling of different ecological niches. *A. terreus* and *A. fumigatus* were the most isolated species (29%) from immunocompromised patients and *A. terreus* was the most recovered species from respiratory samples (9/27, 33%), followed by *A. fumigatus* (6/27, 22%). Infections caused by *A. terreus* are of concern due to its reduced susceptibility to AMB *in vitro* and *in vivo* (Sutton et al., [@B88]; Walsh et al., [@B101]). This species was also found to be prevalent in Tyrol, Austria, from environmental and clinical sources (Lass-Florl et al., [@B57]; Lackner et al., [@B56]). Moreover, a previous multicentre study from the United States reported that the incidence of *A. terreus* following HSCT and SOT was found to be 16 and 11.8%, respectively (Morgan et al., [@B65]).

The majority of *Aspergillus* spp. were isolated from patients with non-invasive infections and a low rate of IA was observed in our study. *Aspergillus* rhinosinusitis was the second highest clinical presentation (23/67, 34.3%) after respiratory infections. These findings are in accordance with a report by Taj-Aldeen et al. ([@B92]), which estimated the burden of fungal infections in Qatar (Taj-Aldeen et al., [@B92]). The study reported that *Aspergillus* rhinosinusitis in Qatar has a relatively high rate (2.31 cases/100,000 individuals). This is attributed to the hot and arid climate in the country and atopic young patients who develop allergic *Aspergillus* rhinosinusitis, in addition to the high number of residents who came from countries with elevated incidences of *Aspergillus* rhinosinusitis (Taj-Aldeen et al., [@B93], [@B94], [@B92]). The human population of Qatar is extremely mixed with high number of Southeast Asians, particularly Indians. In our set, the majority (13/23, 57%) of patients affected with *Aspergillus* rhinosinusitis originated from Southeast Asia and more than half of them (*n* = 7/13, 54%) were from India. Additionally, 4/13 (31%), patients were from Sudan. Previous reports showed that *Aspergillus* rhinosinusitis is common in these regions (Milošev et al., [@B63]; El Daoud et al., [@B28]; Chatterjee and Chakrabarti, [@B17]; Garg et al., [@B32]; Chakrabarti et al., [@B16]; Jain et al., [@B45]; Krishnan et al., [@B52]; Mahgoub et al., [@B60]). Two patients with *Aspergillus* rhinosinusitis, one of which infected with *A. flavus* and the other by *A. fumigatus*, died due to extension of the fungus to the brain ([Table 1](#T1){ref-type="table"}). Two patients were immunocompromised, one patient who was infected with *A. tubingensis* suffered from breast cancer. The other patient presented with nephrotic syndrome and received immunosuppressive therapy, and was infected with *A. terreus*. The latter case was proven by histology ([Table 1](#T1){ref-type="table"}).

Taj-Aldeen et al. ([@B92]) also showed that among respiratory aspergillosis in Qatar the rate of infection for chronic pulmonary aspergillosis post-tuberculosis (CPA-TB) was 0.75/100 000 and the other CPA was 26.82/100,000. Allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS) were more common at 60.2/100 000 and 79.46/100 000, respectively (Taj-Aldeen et al., [@B92]). We were unable to retrieve the complete set of clinical details about the manifestation of aspergillosis. The available clinical presentations are presented in [Table 1](#T1){ref-type="table"}. Overall, most of the isolates showed low MIC values for the systemic antifungal agents investigated. PCZ was the most active drug with MICs ranging from 0.03 to 0.5 μg/ml ([Table 5](#T5){ref-type="table"}). Echinocandins are generally potent against *Aspergillus* spp. and are used as salvage therapy or in combination with other classes of antifungal drugs (Patterson et al., [@B76]). However, a recent report detected a point mutation in the fks1 gene of a strain of *A. fumigatus*, which caused echinocandin resistance and subsequent treatment failure (Jimenez-Ortigosa et al., [@B46]). We observed echinocandin resistance in one strain of *A. fumigatus* with high MECs for ANID and MICA i.e., 4.0 and 16 μg/ml, respectively. Another strain of *A. fumigatus* showed a MIC of 2.0 μg/ml for ITC and was categorized as NWT based on CLSI ECVs (Clinical and Laboratory Standards Institute \[CLSI\], [@B24]). VRC, POS, and ISA MICs for the same strain were 1, 0.25 and 0.25 μg/ml, respectively, which were categorized as WT based on CLSI ECVs (Espinel-Ingroff et al., [@B30]). These findings need to be investigated by analyzing the molecular mechanism(s) of resistance. One *A. flavus* strain showed high MIC of 16 μg/ml for AMB and therefore is considered to be non-wild type (NWT) based on CLSI ECVs. Previous studies have shown that *in vitro* resistance of *A. flavus* to AMB is correlated with treatment failure (Hadrich et al., [@B38]; Barchiesi et al., [@B9]). Most of the *A. terreus* strains, a species that is considered as intrinsically resistant to AMB (Lass-Florl et al., [@B57]), showed high MIC values for AMB (range; 0.25--8.0 μg/ml). *A. chevalieri* failed to grow in susceptibility medium due to its xerophilic nature, therefore, no MIC values were determined.

Patients\' therapeutic outcome was not calculated in our study since the data set was incomplete. We were able to retrieve the antifungal therapeutic regimes for 26 out of 67 patients indicated in [Table 1](#T1){ref-type="table"}. Therapy was dependent on the site of infection and underlying disease. In short, patients with IA (*n* = 6): 2 received ITC, 2 ITC, and VCZ, 1 received ITC in addition to AMB, VCZ and fluconazole, and 1 was treated with VCZ and caspofungin; immunocompromised patients (*n* = 5): 1 was treated with AMB and caspofungin, 1 with VCZ and AMB, 1 with caspofungin, fluconazole, miconazole and VCZ, and 2 patients each with VCZ and miconazole; patients diagnosed with fungal rhinosinusitis (*n* = 9): 8 received either VCZ and/or ITC, and 1 treated with VCZ in addition to caspofungin. Patients with respiratory *Aspergillus* infection or colonization (*n* = 11): 4 received VCZ, 2 treated with ITC, 1 with caspofungin, 1 with caspofungin and AMB, 1 with AMB, caspofungin and VCZ, 1 with ANID, and 1 patient received miconazole probably for a superficial infection. Among 3 patients who died within 30 days of diagnosis, 1 was treated with caspofungin, miconazole and VCZ, 1 with VCZ, and 1 with ANID. For patients treated with multiple antifungal drugs, it was unknown whether the drugs were administered singly or in combinations.

The current study highlights the molecular identification and antifungal susceptibility profiles of 70 clinical *Aspergillus* species in Qatar. Future studies with larger sample size, including clinical and environmental samples, would provide more insight into the epidemiology of clinical aspergilli in the country.

Conclusion {#s5}
==========

In conclusion, we report the molecular identification and *in vitro* antifungal susceptibility profiles of 70 *Aspergillus* spp. recovered from various clinical specimens in Qatar. Rare and cryptic *Aspergillus* species with variable antifungal susceptibilities were detected. Triazole resistance, and recently Echinocandin resistance, is emerging in many parts of the world. Further investigation of resistance mechanism(s) is warranted for species with reduced susceptibilities to antifungal drugs. Infectious disease physicians must be aware of the emerging and resistant species to decide on accurate treatment and improved clinical outcomes.
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